## SUPPLEMENTAL FIGURES

## Multi-omic profiling of cutaneous leishmaniasis infections reveals microbiota-driven mechanisms underlying disease severity

Camila Farias Amorim<sup>1</sup>, Victoria M. Lovins<sup>2</sup>, Tej Pratap Singh<sup>1</sup>, Fernanda O. Novais<sup>3</sup>, Jordan C. Harris<sup>2</sup>, Alexsandro S. Lago<sup>4</sup>, Lucas P. Carvalho<sup>4,5</sup>, Edgar M. Carvalho<sup>4,5</sup>, Daniel P. Beiting<sup>1</sup>, Phillip Scott<sup>1\*</sup>, Elizabeth A. Grice<sup>2\*</sup>

<sup>1</sup>Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States
<sup>2</sup>Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States
<sup>3</sup>Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, Ohio, 43210, United States
<sup>4</sup>Laboratório de Pesquisas Clínicas do Instituto de Pesquisas Gonçalo Muniz – Fiocruz, Salvador, Bahia, 40296-710, Brazil
<sup>5</sup>Immunology Service, Professor Edgard Santos University Hospital Complex, Federal University of Bahia, Salvador, Bahia, 40110-060, Brazil.

\*Corresponding authors. Email: <a href="mailto:egrice@pennmedicine.upenn.edu">egrice@pennmedicine.upenn.edu</a>, <a href="mailto:pscott@vet.upenn.edu">pscott@vet.upenn.edu</a>, <a href="mailto:pscott@vet.upenn.edu">pscott@vet.upenn.edu</a>)

*Supplemental Figure 1. Study design, clinical metadata, and dataset sample inventory.* A) A schematic summarizing the sample types and time points of collection for this study. B) Venn diagram indicates the number of biopsies and swabs for 16S-seq collected from the same lesion and patient. C) A heatmap describes the sample inventory for each participating patient and their associated clinical metadata.



E	Biop	sy			5	Swa	bs												
Time point (days):	0	0	30	60	90	120	150	180	210	240	PatientID	age	sex	Lesion size (mm <sup>2</sup> )	Lymphaden opathy	DTH (mm <sup>2</sup> )	Treatment Outcome*/**	Healing time (Davs)	Treatment
											Patient1	16-20	male	132	ves	132	DOT	DOT	DOT
•											Patient2	16-20	male	400	yes	144	Failure	180	antimony
											Patient3	31-35	female	525	no	110	Cure	90	antimony
											Patient4	16-20	male	645	yes	120	Failure	210	antimony
											Patient5	26-30	male	646	yes	225	DOT	DOT	DOT
											Patient6	21-25	male	99	yes	140	Cure	49	antimony
											Patient7	16-20	male	1800	no	130	Failure	221	antimony
											Patient8	41-45	male	100	yes	130	Failure	147	antimony
						⊢					Patient9	21-25	female	580	yes	210	Failure	221	antimony
					└─	⊢	L				Patient10	56-60	female	234	yes	144	Cure	98	antimony
				L		⊢	L				Patient11	31-35	male	90	yes	144	DOT	DOT	DOT
		_		⊢		⊢	⊢				Patient12	16-20	male	196	yes	120	DOT	DOT	DOT
						-	⊢				Patient13	26-30	male	1470	yes	225	Cure	90	antimony
•	_				_	-			_		Patient14	46-50	male	1025	yes	120	Failure	221	antimony
		_				-					Patient15	26-30	temale	357	yes	195	DOT	001	DOT
	_	_	_		-						Patient16	16-20	female	480	yes	130	Failure	120	antimony
•	_	_	_	_		-					Patient17	21-25	remale	204	no	252	Cure	45	antimony
	_	_	_		-	-					Patient18	21-25	male	240	yes	225	Fallure	210	antimony
•	-		_	-	-		-				Patient20	21-25	male	1050	yes	192	Eailuro	110	antimony
	_		_	-	-		-				Patient21	21-25	male	F00	yes	240	Cure	75	antimony
	_					-					Patient22	16-20	male	1221	yes	140	Failure	210	antimony
						-					Patient23	46-50	female	280	yes	210	Failure	127	antimony
											Patient24	26-30	male	72	Ves	100	Failure	150	antimony
						-					Patient25	21-25	male	500	Ves	121	Cure	110	antimony
				-		-					Patient26	31-35	male	360		144	Failure	125	antimony
					-						Patient27	41-45	female	110	no	165	Cure	75	antimony
											Patient28	26-30	male	375	Ves	99	Failure	110	antimony
							-				Patient29	21-25	female	306	ves	132	Cure	90	antimony
											Patient30	21-25	female	300	no	225	Cure	20	antimony
											Patient31	26-30	male	740	no	90	Cure	47	antimony
											Patient32	31-35	female	200	yes	240	Failure	130	antimony
											Patient33	51-55	male	800	yes	323	Cure	40	antimony
											Patient34	16-20	male	120	no	832	Cure	40	antimony
											Patient35	16-20	male	216	yes	195	Failure	120	antimony
											Patient36	31-35	female	150	no	180	DOT	DOT	DOT
											Patient37	46-50	male	323	no	225	DOT	DOT	DOT
•											Patient38	41-45	male	300	yes	192	Cure	50	antimony
											Patient39	46-50	male	550	yes	169	DOT	DOT	DOT
						⊢					Patient40	31-35	male	300	no	120	Failure	305	antimony
•					-	-					Patient41	31-35	male	532	no	99	Failure	120	antimony
				-		⊢	-		$\square$		Patient42	21-25	maie	300	yes	121	Cure	30	antimony
			-	-	-		-		$\vdash$		Patient43	26-30	temale	360	yes	156	DOT	190	DOT
				-		⊢	-		$\vdash$		Patient44	41-45	fomale	513	yes	100	Failure	180	antimony
				-		⊢	-		$\vdash$		Patient45	21-25	female	450	no	225	Gure	/0	antimony
				-			-		$\vdash$		Patient40	26-30	fomale	405	no	90	Failure	250	antimony
-				-	-	⊢	-		$\vdash$		Patient48	36-40	female	270	no	156	Failure	100	antimony
•				-			-		$\vdash$		Patient49	31-35	female	684	10	156	Failure	150	antimony
				-			⊢				Patient50	16-20	male	120	VAS	81	Cure	63	antimony
<b>_</b>				-	-		-		$\vdash$		Patient51	21-25	male	240	Ves	204	Cure	64	antimony
•				-	-	-	-		-		Patient52	21-25	male	275	ves	285	Failure	220	antimony
						-	-		$\square$		Patient53	31-35	male	360	Ves	196	Cure	55	antimony
٠									$\square$		Patient54	16-20	male	40	ves	56	Failure	135	antimony
•						-					Patient55	21-25	female	540	ves	225	Cure	40	antimony
											Patient56	26-30	male	240	ves	195	Cure	37	antimony
٠											Patient57	31-35	male	294	yes	225	Failure	180	antimony
•											Patient58	16-20	male	108	yes	156	Cure	25	antimony
											Patient59	31-35	female	230	no	180	Failure	180	antimony
											Patient60	31-35	female	35	yes	240	Cure	20	antimony
											Patient61	36-40	male	154	no	100	Failure	105	antimony
•	_									_	Patient62	26-30	male	16	yes	272	Failure	130	antimony

Sample in the study's inventory

Staphylococcus aureus isolate from D0, included in the pan-genome reference

С

\*DOT = patients were treated with an alternative ongoing  $\underline{D}rug \underline{O}n \underline{T}rial$  at the endemic area

\*\*Cure = 1 round of antimony, Failure = 2-3 rounds of antimony

Table also as Supplemental Table 1

Supplemental Figure 2. Microbiome clusters definitions and association with clinical metadata. A) Unsupervised hierarchical clustering (HC) analysis with Ward.D2 clustering method were calculated from a relative abundance matrix of top 10 taxa to classify samples into eight distinct microbiome profiles, or "clusters". A consensus of relative abundance means per sample, and number of dominant taxa in the community (>80% of total dominance and >2, respectively) were used as thresholds to cluster the microbiome groups. B) Multivariate linear regression analysis was calculated between the Microbiome clusters (M0-M7) and clinical metadata using the lm() function in R.





Multivariate linear regression model: Microbiome cluster vs. Age, Sex, Lesion size, DTH, Lymphadenopathy										
Estimate Std.Error t value Pr(>										
(Intercept)	4.014651	2.5935503	1.548	0.13						
Age	0.0010747	0.0395538	0.027	0.978						
Sex	0.6015822	0.8833021	0.681	0.5						
Lesion size (mm2)	0.0006427	0.0010042	0.64	0.526						
DTH (mm2)	-0.0015454	0.0033215	-0.465	0.644						
Lymphadenopathy	-0.4494788	0.9347437	-0.481	0.633						
Microbiome cluster residuals: Min=-4.6844; 1Q=-1.3933; Median=0.9822; 3Q=1.6368; Max=2.8452 Residual standard error: 2.466 on 39 degrees of freedom Multiple R-squared=0.0483; Adjusted R-squared=-0.07371; E-statistic=0.3959; on 5 and 39 DE: covalue: 0.8486										

Supplemental Figure 3. Impact of different microbiome dysbiosis in the lesion healing time in patients infected by L. braziliensis. A) Survival curves for the healing time for lesions of patients from M1, M2, M3, M4, M5, M7 vs. M0 cluster. Patients who received an alternative form of treatment from an ongoing clinical trial in the clinic were not considered or added to the clinical outcome-related analysis. Log-rank (Mantel-Cox) test was used to calculate the statistical significance. B) PCoA showing component 1 calculated from weighted UniFrac dissimilarity analysis, including longitudinal swab samples from the M1, M2, M3, M4, M5, M7 and M0 clusters (Day0-Day210) and swab samples from the contralateral skin of the same patient. Patients were divided for analysis according to the number of Sbv rounds required for complete healing (1 vs. >1 round of Sbv). The connecting lines indicate samples collected from the same patient over time. C) Antimony therapy does not affect unaffected skin microbiome (contralateral skin). PCoA calculated from weighted UniFrac dissimilarity analysis including longitudinal swab samples from the same patient and ysis including longitudinal swab samples from the same patient and ysis including longitudinal swab samples from the same patient over time. C) Antimony therapy does not affect unaffected skin microbiome (contralateral skin). PCoA calculated from weighted UniFrac dissimilarity analysis including longitudinal swab samples from the lesion and contralateral skin of CL patients at Day0 and Day90. Lines connect samples from the same patients. Only patients treated with Sb<sup>v</sup> and with samples available from those two time points were included in this analysis.



Supplemental Figure 4. Principal Component Analysis (PCA) on whole host transcriptome with patients with distinct microbiome clusters. Principal Component Analysis (PCA) showing the principal component (PC) 1 and PC2 for RNA-seq data from CL lesions with microbiome cluster available, n=35 (characterized from the 16S-seq analysis) and Healthy skin (HS), n=7.



Supplemental Figure 5. Principal Component Analysis (PCA) on ViTALs showing gene loadings. PCA showing the PC1 and PC2 for ViTALs from CL lesions with microbiome cluster available, n=35 (characterized from the 16S-seq analysis). This PCA is part of the Step 3 from our dataset dimensionality reduction computational workflow. In pink, genes named as "Immunoglobulin"-encoding genes. PCA, Principal Component Analysis. PC, Principal components. ViTALs, highly variable CL-associated transcripts.



Supplemental Figure 6. Staphylococcus isolates from CL lesions and associated clinical metadata and RNA-seq/16S-seq results. A) 13 S. aureus isolates were short-read whole genome sequenced and combined with 22 publicly available S. aureus genomes to build out in-house S. aureus pangenome. A Hierarchical clustering was performed between the S. aureus genomes, together with a publicly available S. epidermidis genome to serve as comparison. B) Clinical metadata, RNA-seq and 16S-seq-associated data from the lesions where the CL S. aureus isolates originated from. C) Distribution of lesion biopsies according to the S. aureus transcript abundances (in log10 counts per million, CPM).



Β

								Lesion Biopsy						
					Clinica	I metadata	16S-seq (swab) Microbiome profile	RNA-seq	qPCR					
	Cluster	CL <i>S.</i> Age aureus		Sex	Lesion size (mm2)	Lymphade nopathy	Healing time (days)	Clinical Outcome*	Microbiome cluster	<i>S. aureus</i> (CPM)	Bacterial load	Parasite load		
	1	CLSA62	26-30	male	0-25th	yes	130	> 1 Sb <sup>v</sup>	NA	NA	NA	NA		
	2	CLSA38	41-45	male	50-75th	yes	50	1 Sb <sup>v</sup>	NA	>75th	>75th	>75th		
	3	CLSA2	2 16-20 male 16 16-20 male	male	50-75th 50-75th	yes yes	180	> 1 Sb <sup>v</sup>	M6	>75th	>75th	>75th		
	3	CLSA16		male			120	> 1 Sb <sup>v</sup>	M7	>75th	25-50th	>75th		
0	3	CLSA19	21-25	25         male         50-75th         yes           25         male         25-50th         yes	72	1 Sb <sup>v</sup>	M7	>75th	25-50th	50-75th				
jč	3	CLSA51	21-25		yes	64	1 Sb <sup>v</sup>	NA	50-75th	25-50th	50-75th			
L L	4	CLSA41	31-35	male	>75th	no	120	> 1 Sb <sup>v</sup>	NA	>75th	>75th	25-50th		
ġ.	5	CLSA14	46-50	male	>75th	yes	221	> 1 Sb <sup>v</sup>	M6	25-50th	>75th	>75th		
ě 🔶	5	CLSA50	16-20	male	0-25th	yes	63	1 Sb <sup>v</sup>	NA	>75th	0-25th	50-75th		
for	5	CLSA57	31-35	male	25-50th	yes	180	> 1 Sb <sup>v</sup>	M6	NA	NA	NA		
eq	6	CLSA17	21-25	female	e 25-50th no	45	1 Sb <sup>v</sup>	M6	25-50th	50-75th	0-25th			
ş	6	CLSA48	36-40	female	25-50th	no	100	> 1 Sb <sup>v</sup>	NA	>75th	0-25th	>75th		
<u>a</u>	6	CLSA54	16-20	male	0-25th	yes	135	> 1 Sb <sup>v</sup>	M6	NA	NA	NA		
	For continuous variables: >75th quartile 50-75th quartile 25-50th quartile 0-25th quartile													

Relative to values in the entire cohort of 62 patients

\*1 round of antimony Sbv = Cure, >1 round of antimony Sbv = Failure

## Α



Supplemental Figure 7. Number of CD90.2-,  $\alpha\beta T$  cells and CD4+ T cells in S. aureus and L. braziliensis treatment protocol in C57BL/6 mice, with blockade of IL-1 $\alpha$ , IL-1 $\beta$  and IL-1R with monoclonal antibodies. Number of CD90.2-,  $\alpha\beta T$  cells and CD4+ T cells recovered from the co-infected ears in week six. Non-parametric Mann-Whitney test was used for statistical significance, \*P<0.05, \*\*P<0.01, \*\*\*P<0.001. Violin plots and median are represented in the plots when appropriate.

